Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner sold 8,791 shares of the company’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $19.70, for a total value of $173,182.70. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of EXEL stock traded up $0.65 during trading hours on Friday, reaching $20.31. The company had a trading volume of 3,573,829 shares, compared to its average volume of 4,446,562. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.54 and a current ratio of 8.66. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $32.20. The firm has a market cap of $5.88 billion, a P/E ratio of 39.82, a price-to-earnings-growth ratio of 1.17 and a beta of 2.29.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business had revenue of $225.40 million during the quarter, compared to analyst estimates of $174.14 million. During the same quarter last year, the firm earned $0.26 earnings per share. The company’s revenue for the quarter was up 47.8% compared to the same quarter last year. On average, equities research analysts predict that Exelixis, Inc. will post 1.3 EPS for the current year.
Several equities research analysts have commented on EXEL shares. Morgan Stanley started coverage on Exelixis in a research note on Monday, September 10th. They set an “underweight” rating and a $19.00 price target for the company. Goldman Sachs Group started coverage on Exelixis in a research note on Monday, September 17th. They set a “neutral” rating and a $22.00 price target for the company. BidaskClub upgraded Exelixis from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 29th. Piper Jaffray Companies dropped their price target on Exelixis from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 5th. Finally, Oppenheimer set a $40.00 price target on Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 15th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Exelixis presently has a consensus rating of “Buy” and a consensus target price of $29.44.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2018/12/01/exelixis-inc-exel-cfo-sells-173182-70-in-stock.html.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Further Reading: What are the benefits of a balanced fund?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.